Nichi-Iko Pharmaceutical Co., Ltd. (NHKFF) est une société cotée en bourse dans le Santé secteur, opérant dans le Drug Manufacturers - Specialty & Generic secteur d'activité. Le siège social de l'entreprise est situé à Toyama, Japan. Le PDG actuel est Shingo Iwamoto.
NHKFF a date d'introduction en bourse 2020-05-26, 2,656 employés à temps plein, cotée sur le Other OTC.
Nichi-Iko Pharmaceutical Co., Ltd. manufactures, sells, and distributes various pharmaceutical products. It operates through two segments, Nichi-Iko Group and Sagent Group. The company primarily focuses on the production of generic drugs. It offers antidiabetic agents, antacids, antireflux agents, beta-blocker, hypnotic and sedative, angiotensin ? antagonist, angiotensin ? antagonist/diuretic combination, dyslipidaemic agent, and calcium antagonist products, as well as chemotherapeutic agents. The company also provides treatments for circulatory, digestive, respiratory, nervous system, allergies, and others. It supplies its products to medical institutions, including hospitals, clinics, dispensing pharmacies, etc. The company was formerly known as Nihon Iyakuhin Kogyo Co., Ltd. and changed its name to Nichi-Iko Pharmaceutical Co., Ltd. in 2005. Nichi-Iko Pharmaceutical Co., Ltd. was incorporated in 1947 and is headquartered in Toyama, Japan.
